Hematopoietic stem cell transplant recipients surviving at least 2 years from transplant have survival rates approaching population levels in the modern era of transplantation.

[1]  M. Sorror,et al.  Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts , 2020, Annals of Internal Medicine.

[2]  W. Wood,et al.  Long‐term outcomes among 2‐year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b‐cell lymphoma , 2018, Cancer.

[3]  M. Solh,et al.  Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients , 2018, Bone Marrow Transplantation.

[4]  J. Szer,et al.  Activity and Capacity Profile of Transplant Physicians and Centers in Australia and New Zealand. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  J. Ritz,et al.  Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Bhatia,et al.  How I monitor long-term and late effects after blood or marrow transplantation. , 2017, Blood.

[7]  S. Pavletic,et al.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  M. Solh,et al.  Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  I. Moiseev,et al.  Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  R. Storb,et al.  Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. , 2016, Blood.

[11]  J. Szer,et al.  A Review of Hematopoietic Cell Transplantation in Australia and New Zealand, 2005 to 2013. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  T. Panzarella,et al.  Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. , 2016, The Lancet. Oncology.

[13]  Giuseppe Milone,et al.  Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. , 2016, The New England journal of medicine.

[14]  H. Nakasone,et al.  Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  M. Boccadoro,et al.  Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.

[16]  A. Gennery,et al.  Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015 , 2015, Bone Marrow Transplantation.

[17]  Karl Frauendorfer,et al.  One million haemopoietic stem-cell transplants: a retrospective observational study. , 2015, The Lancet. Haematology.

[18]  A. Tichelli,et al.  Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  M. Boccadoro,et al.  Autologous transplantation and maintenance therapy in multiple myeloma. , 2014, The New England journal of medicine.

[20]  K. Kuntz,et al.  Prevalence of hematopoietic cell transplant survivors in the United States. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  Stephanie J. Lee,et al.  Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Nademanee,et al.  Conditional Survival and Cause-specific Mortality after Autologous Hematopoietic Cell Transplantation for Hematological Malignancies , 2012, Leukemia.

[23]  M. Aljurf,et al.  Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. , 2012, Biology of Blood and Marrow Transplantation.

[24]  M. Sorror,et al.  Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Storb,et al.  Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Simpson,et al.  Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  A. Nademanee,et al.  Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. , 2007, Blood.

[28]  Paul W Dickman,et al.  Estimating and modeling the cure fraction in population-based cancer survival analysis. , 2007, Biostatistics.

[29]  P. Dickman,et al.  Interpreting trends in cancer patient survival , 2006, Journal of internal medicine.

[30]  G. Pond,et al.  Long-term survival after blood and marrow transplantation: comparison with an age- and gender-matched normative population. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  Paul W Dickman,et al.  Regression models for relative survival , 2004, Statistics in medicine.

[32]  J. V. Stone,et al.  Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation , 1999 .